I am a viral immunologist (Ph.D. McGill, 2000) who is recognized as a world leader in human immunology, specifically immunity to hepatitis C virus (HCV) (>90 publications). Research accomplished during my post-doctoral training established the essential and complementary roles of CD8+ and CD4+ T cells in resolution and protection from persistent HCV infection in the chimpanzee non-human primate model (Grakoui et al., 2003; Shoukry et al., 2003). Since 2005, I have established my independent group at the University of Montreal Hospital Centre (CRCHUM) and a translational research program focused on studying immunity to HCV using unique patient cohorts like people who inject drugs (PWIDs) at high risk of HCV infection. More recently, my research has expanded to studying immunological mechanisms of liver inflammation and fibrosis progression and development of hepatocellular carcinoma (HCC). Recent findings from my group have characterized the role of type 3 cytokines IL-17A and IL-22 in liver fibrosis. My research was/is funded by the Canadian Institutes of Health Research (CIHR), Fonds de recherche du Québec – Santé (FRQS), the Dana Foundation, the Canadian Foundation for Aids Research (CANFAR), the Canadian Liver Foundation (CLF) and the National Institutes of Health (NIH). I have received numerous awards from the American Liver Foundation, CIHR and FRQS. I have served on various review committees on the national and international level including CIHR, FRQS, CRC, NIH, Wellcome Trust, MRC and DFG. I am an Academic Editor for PLoS One, Viral Immunology and Frontiers in Immunology. In recognition, CIHR profiled my achievements on World Hepatitis Day in 2013 and 2017. In 2019, I was selected as Professor of the Year by the Department of Medicine, University of Montreal and was awarded the CLF 50th Anniversary Recognition Medal.Since 2015, I lead the federally funded Canadian Network on Hepatitis C (CanHepC). This multidisciplinary network regroups >100 investigators, knowledge users and trainees spanning all four CIHR research pillars (Basic, Clinical, Epidemiology and health services) with the goal of establishing a pipeline from discovery to implementation to improve the quality of life of persons infected with HCV, and to work towards the eradication of HCV in Canada. Specialties: Medical Research, Translational Research, Human Immunology, Viral Hepatitis, Liver disease